PL3313865T3 - Syntetyczne związki peptydowe i sposoby zastosowania - Google Patents

Syntetyczne związki peptydowe i sposoby zastosowania

Info

Publication number
PL3313865T3
PL3313865T3 PL16815455T PL16815455T PL3313865T3 PL 3313865 T3 PL3313865 T3 PL 3313865T3 PL 16815455 T PL16815455 T PL 16815455T PL 16815455 T PL16815455 T PL 16815455T PL 3313865 T3 PL3313865 T3 PL 3313865T3
Authority
PL
Poland
Prior art keywords
methods
synthetic peptide
peptide compounds
compounds
synthetic
Prior art date
Application number
PL16815455T
Other languages
English (en)
Inventor
Neel K. Krishna
Kenji Cunnion
Original Assignee
Realta Holdings, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Realta Holdings, Llc filed Critical Realta Holdings, Llc
Publication of PL3313865T3 publication Critical patent/PL3313865T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/12011—Astroviridae
    • C12N2770/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PL16815455T 2015-06-26 2016-06-24 Syntetyczne związki peptydowe i sposoby zastosowania PL3313865T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562185202P 2015-06-26 2015-06-26
PCT/US2016/039421 WO2016210370A2 (en) 2015-06-26 2016-06-24 Synthetic peptide compounds and methods of use
EP16815455.7A EP3313865B1 (en) 2015-06-26 2016-06-24 Synthetic peptide compounds and methods of use

Publications (1)

Publication Number Publication Date
PL3313865T3 true PL3313865T3 (pl) 2021-10-25

Family

ID=57586008

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16815455T PL3313865T3 (pl) 2015-06-26 2016-06-24 Syntetyczne związki peptydowe i sposoby zastosowania

Country Status (7)

Country Link
US (1) US10933116B2 (pl)
EP (1) EP3313865B1 (pl)
JP (2) JP6820917B2 (pl)
CA (1) CA2987141A1 (pl)
ES (1) ES2875498T3 (pl)
PL (1) PL3313865T3 (pl)
WO (1) WO2016210370A2 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10947279B2 (en) 2015-06-26 2021-03-16 Realta Holdings, Llc Synthetic peptide compounds and methods of use
KR102420552B1 (ko) * 2018-01-09 2022-07-13 레알타 홀딩스, 엘엘씨 동물 모델에서의 미엘로퍼옥시다제 산화 활성의 pic1 억제
WO2020168036A1 (en) * 2019-02-15 2020-08-20 Eastern Virginia Medical School Pic1 variants with improved solubility and methods of using the same
WO2022072272A2 (en) * 2020-09-30 2022-04-07 Realta Life Sciences, Inc. Peptides and methods of use
CN116528886A (zh) * 2020-11-02 2023-08-01 瑞尔塔生命科学公司 肽及其使用方法
IL302391A (en) * 2020-11-02 2023-06-01 Realta Life Sciences Inc Peptides and methods of use
MX2023005395A (es) * 2020-11-09 2023-05-19 Realta Life Sciences Inc Formulaciones de peptidos y metodos de uso.
WO2022191194A1 (ja) * 2021-03-12 2022-09-15 国立大学法人 新潟大学 横紋筋融解により誘発される腎障害の抑制
EP4205736A4 (en) * 2021-03-12 2024-06-12 Niigata University PREVENTION OF KIDNEY INJURY INDUCED BY HEMOLYTIC REACTION

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625049A (en) 1993-05-12 1997-04-29 Us Health Nucleic acids encoding human astrovirus serotype 2
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
AU3066699A (en) 1998-03-03 1999-09-20 Johns Hopkins University, The Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
AU2729400A (en) 1999-01-19 2000-08-07 James Daly Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease
US6696562B1 (en) 2000-07-10 2004-02-24 The United States Of America As Represented By The Secretary Of Agriculture Avian astrovirus
US20070116672A1 (en) 2003-09-05 2007-05-24 Kotwal Girish J Treatment of rheumatic diseases
WO2005023195A2 (en) 2003-09-05 2005-03-17 University Of Louisville Research Foundation, Inc. Treatment of spinal cord injury
DE602004021946D1 (de) 2003-09-05 2009-08-20 Tonen Sekiyukagaku Kk Verfahren zur herstellung einer mikroporösen folie aus thermoplastischem harz
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
US7381524B2 (en) 2003-10-10 2008-06-03 Wisconsin Alumni Research Foundation Method to detect antibodies specific for type-2 turkey astrovirus
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CA2655371C (en) 2006-06-15 2017-06-20 Eastern Virginia Medical School Methods for regulating complement cascade proteins using astrovirus coat protein and derivatives thereof
CA2688693A1 (en) 2007-04-11 2008-10-23 Pestka Biomedical Laboratories, Inc. Interferons of rhesus and cynomolgus origin and uses thereof
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
EP2561367A1 (en) 2010-04-22 2013-02-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations
US10005818B2 (en) 2010-07-21 2018-06-26 Realta Holdings, Llc Derivative peptide compounds and methods of use
CA2804998C (en) 2010-07-21 2018-11-13 Eastern Virginia Medical School Peptide compounds to regulate the complement system
EP2838550A1 (en) * 2012-03-16 2015-02-25 Belrose Pharma Inc. Polymeric conjugates of c1-inhibitors

Also Published As

Publication number Publication date
CA2987141A1 (en) 2016-12-29
ES2875498T3 (es) 2021-11-10
WO2016210370A2 (en) 2016-12-29
JP6992201B2 (ja) 2022-02-03
US10933116B2 (en) 2021-03-02
JP2018524402A (ja) 2018-08-30
EP3313865A4 (en) 2019-05-15
EP3313865A2 (en) 2018-05-02
EP3313865B1 (en) 2021-04-07
US20200254053A1 (en) 2020-08-13
JP6820917B2 (ja) 2021-01-27
JP2021063106A (ja) 2021-04-22
WO2016210370A3 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
IL286316A (en) New micro-dystrophins and related method of use
HK1248231A1 (zh) 取代的喹唑啉化合物和其使用方法
HK1253049A1 (zh) 糖基相互作用化合物及其使用方法
PT3548033T (pt) Compostos e respectivos métodos de utilização
IL251988A0 (en) Compounds acting on glycans and methods of using them
ZA201905677B (en) Glycan-interacting compounds and methods of use
PL3313865T3 (pl) Syntetyczne związki peptydowe i sposoby zastosowania
IL282482A (en) Variants of protoxin-II and methods of use
GB201514760D0 (en) Compounds and method of use
PL3089971T3 (pl) Związki i sposoby ich zastosowania
HK1248122A1 (zh) 抗met抗體及其使用方法
HK1251979A1 (zh) 肽組合物和使用方法
HK1250476A1 (zh) 原毒素-ii變體及使用方法
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
ZA201606450B (en) Compounds and their methods of use
IL247448A0 (en) Peptides and methods of use
GB201421888D0 (en) Peptides derived from mysoin 19 and methods of use thereof
GB201403697D0 (en) Compounds and methods of use
GB201504211D0 (en) Use of peptides